In a filing, Relay Therapeutics Inc. revealed its President, R&D Bergstrom Donald A unloaded Company’s shares for reported $0.18 million on Nov 01. In the deal valued at $22.75 per share,8,000 shares were sold. As a result of this transaction, Bergstrom Donald A now holds 86,866 shares worth roughly $ 1.78 million.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Then, Bergstrom Donald A sold 1,817 shares, generating $39,138 in total proceeds. Upon selling the shares at $21.54, the President, R&D now owns 86,866 shares.
Before that, Adams Brian sold 728 shares. Relay Therapeutics Inc. shares valued at $15,681 were divested by the Chief Legal Officer at a price of $21.54 per share. As a result of the transaction, Adams Brian now holds 61,820 shares, worth roughly $1.27 million.
Barclays initiated its Relay Therapeutics Inc. [RLAY] rating to an Equal weight in a research note published on Friday, September 30, 2022; the price target was $23. PT values the company’s stock at a premium of 10.91 to its Friday closing price. A number of analysts have revised their coverage, including Stifel’s analysts, who began to cover the stock in early September with a ‘”a Buy”‘ rating. Jefferies began covering RLAY with “an Underperform” recommendation on June 06, 2022. Berenberg started covering the stock on February 01, 2022. It rated RLAY as “a Buy”.
Price Performance Review of RLAY
On Friday, Relay Therapeutics Inc. [NASDAQ:RLAY] saw its stock fall -2.15% to $20.49. On the same session, the stock had its day’s lowest price of $20.12, but rose to a high of $21.86. Over the last five days, the stock has lost -8.93%. Relay Therapeutics Inc. shares have fallen nearly -33.28% since the year began. Nevertheless, the stocks have fallen -43.68% over the past one year. While a 52-week high of $37.52 was reached on 04/04/22, a 52-week low of $12.65 was recorded on 06/14/22. SMA at 50 days reached $22.87, while 200 days put it at $22.12. A total of 0.83 million shares were traded, compared to the trading of 0.53 million shares in the previous session.
Levels Of Support And Resistance For RLAY Stock
The 24-hour chart illustrates a support level at 19.79, which if violated will result in even more drops to 19.08. On the upside, there is a resistance level at 21.53. A further resistance level may holdings at 22.56. The Relative Strength Index (RSI) on the 14-day chart is 43.47, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.20, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 67.64%. Stochastics %K at 44.65% indicates the stock is a holding.
How much short interest is there in Relay Therapeutics Inc.?
A steep rise in short interest was recorded in Relay Therapeutics Inc. stocks on Jul 14, 2022, growing by 0.66 million shares to a total of 19.02 million shares. Yahoo Finance data shows the prior-month short interest on Jun 14, 2022 was 18.36 million shares. There was a rise of 3.47%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 30.77% of the overall stock float, the days-to-cover ratio (short ratio) rose to 13.87.
Relay Therapeutics Inc. [RLAY] – Who Are The Largest Shareholders?
In filings from Fidelity Management & Research Co, it is revealed that the company now owns 12,332,702 shares, or roughly 11.33% of the outstanding RLAY shares. In other words, the investor’s shares have fallen by -2,962,728 from its previous 13-F filing of 15295430.0. Additionally, The Vanguard Group, Inc. increased 15.19% of its stake after which the total value it holdings stand at $156,063,321, while BlackRock Fund Advisors added 9.89% of its stake to hold $119.13 million in the firm. Over the last quarter, T. Rowe Price Associates, Inc. purchased 300,589 shares of Relay Therapeutics Inc., while SSgA Funds Management, Inc. bought 1,524,727 shares. At present, BVF Partners LP is holding 4,384,805 shares valued at $98.09 million. Casdin Capital LLC owned 4,068,574 shares of the company at the time of its most recent 13F filing, worth $91.01 million.
According to FactSet, Relay Therapeutics Inc.’s share price will average $37.90 in the next year, based on opinions of analysts polled by the firm. This is up nearly 88.63 percent from its previous closing price of $20.94. Analysts expect Relay Therapeutics Inc. stock to reach the higher price of $50.00, while the lowest price estimate is $16.00. However, 11 analysts have rated RLAY stock as an Overweight in their predictions for 2022. The most recent change occurred on July 21, 2021 when BofA Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $50 price target.